News
CVM
0.4170
+2.94%
0.0119
Weekly Report: what happened at CVM last week (0203-0207)?
Weekly Report · 5d ago
Weekly Report: what happened at CVM last week (0127-0131)?
Weekly Report · 02/03 11:24
Weekly Report: what happened at CVM last week (0120-0124)?
Weekly Report · 01/27 11:28
Weekly Report: what happened at CVM last week (0113-0117)?
Weekly Report · 01/20 11:19
CEL-SCI Q4 EPS $(0.09) Beats $(0.11) Estimate
Benzinga · 01/14 14:20
Press Release: CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
Dow Jones · 01/14 14:00
Press Release: CEL-SCI Reports Fiscal 2024 -2-
Dow Jones · 01/14 14:00
Weekly Report: what happened at CVM last week (0106-0110)?
Weekly Report · 01/13 11:19
Weekly Report: what happened at CVM last week (1230-0103)?
Weekly Report · 01/06 11:28
Biotech Alert: Searches spiking for these stocks today
TipRanks · 01/02 16:15
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/30/2024 21:05
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
Benzinga · 12/30/2024 19:14
US Stocks Open Lower; Dow Tumbles 600 Points
Benzinga · 12/30/2024 15:07
What's Going On With Cel-Sci Shares Premarket On Monday?
Benzinga · 12/30/2024 13:21
CEL-SCI prices $5M public offering at 31c per share
TipRanks · 12/30/2024 12:00
Weekly Report: what happened at CVM last week (1223-1227)?
Weekly Report · 12/30/2024 11:22
US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking
Benzinga · 12/30/2024 11:15
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Benzinga · 12/30/2024 09:56
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday
Benzinga · 12/30/2024 08:09
CEL-SCI prices $5 million offering
Seeking Alpha · 12/30/2024 06:06
More
Webull provides a variety of real-time CVM stock news. You can receive the latest news about CEL-SCI Corp through multiple platforms. This information may help you make smarter investment decisions.
About CVM
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).